ZyVersa Therapeutics' stockholders approved several proposals at the 2024 annual meeting, including increasing the shares reserved under the equity incentive plan by 150,000 to a total of 181,795 shares, and the issuance of up to 478,600 shares upon exercise of certain warrants.